Výsledky vyhledávání - "Dennis O. Iyekegbe"

Supplementary Figure S5 from The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood–Brain Barrier in Glioblastoma

Autor: Jann N. Sarkaria, Nathalie Y.R. Agar, William F. Elmquist, Stuart D. Shumway, Bennett Ma, Vincenzo Pucci, Jeanette E. Eckel-Passow, Paul A. Decker, Zhenkun Lou, Debra L. Evans, Mark A. Schroeder, Brett L. Carlson, Katrina K. Bakken, Dustin Mueller, Dennis O. Iyekegbe, Shiv K. Gupta, David Calligaris, Jenny L. Pokorny

Supplementary Figure S5. MALDI-TOF MS analyses of MK-1775 (m/z 501.2)in brain and flank GBM22 tumor samples after treatment with placebo or MK-1775

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::353f8a860b6932933b90938e0a9d0c07
https://doi.org/10.1158/1078-0432.22454537

Zobrazit plný text záznamu

Supplementary Methods and Legend from The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood–Brain Barrier in Glioblastoma

Supplementary Methods and Legend

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::edd5b3cca6382f37122b6f4223c2f884
https://doi.org/10.1158/1078-0432.22454534

Zobrazit plný text záznamu

Data from The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood–Brain Barrier in Glioblastoma

Purpose: Wee1 regulates key DNA damage checkpoints, and in this study, the efficacy of the Wee1 inhibitor MK-1775 was evaluated in glioblastoma multiforme (GBM) xenograft models alone and in combination with radiation and/or temozolomide.Experimental

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e76df6db652fd16b0b9ac0d4b706f5b
https://doi.org/10.1158/1078-0432.c.6522779

Zobrazit plný text záznamu

Supplementary Figure S3 from The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood–Brain Barrier in Glioblastoma

Supplementary Figure S3. Growth inhibition in GBM6, 12 or 22 in response to graded concentrations of MK-1775, TMZ or their combination as assessed by neurosphere formation

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4327a47b6d14607a15b04501a773fe76
https://doi.org/10.1158/1078-0432.22454546

Zobrazit plný text záznamu

Supplementary Figure S2 from The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood–Brain Barrier in Glioblastoma

Supplementary Figure S2. Analysis of DNA damage by immunofluorescence based γH2AX foci formation in GBM6 and GBM22 after MK-1775 or radiation treatment.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0bad7e3416eb5469deeaa4ce032badd6
https://doi.org/10.1158/1078-0432.22454549.v1

Zobrazit plný text záznamu

Supplementary Figure S1 from The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood–Brain Barrier in Glioblastoma

Supplementary Figure S1. Relative quantification of Wee1 transcript in GBM xenograft lines

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8336abd605f74fd8d7a67c8cbba48388
https://doi.org/10.1158/1078-0432.22454552.v1

Zobrazit plný text záznamu

The efficacy of the Wee1 inhibitor MK-1775 combined with temozolomide is limited by heterogeneous distribution across the blood-brain barrier in glioblastoma

Autor: David Calligaris, Mark A. Schroeder, Nathalie Y. R. Agar, William F. Elmquist, Vincenzo Pucci, Jann N. Sarkaria, Bennett Ma, Brett L. Carlson, Dennis O. Iyekegbe, Debra Evans, Stuart D. Shumway, Zhenkun Lou, Katrina K. Bakken, Jeanette E. Eckel-Passow, Paul A. Decker, Shiv K. Gupta, Dustin Mueller, Jenny L. Pokorny

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1903ca90b0a41706344b7f8c62774f0
https://europepmc.org/articles/PMC4401631/

Zobrazit plný text záznamu

Abstract 2617: Preclinical efficacy of GNE-317, a dual PI3K/mTOR inhibitor, with or without bevacizumab in EGFR and/or PTEN-mutated glioblastoma multiforme

Autor: Ann C. Mladek, Terence T. Sio, Jenny L. Pokorny, Laurent Salphati, Brett L. Carlson, Jann N. Sarkaria, Dennis O. Iyekegbe, Heidi S. Phillips, Katrina K. Bakken, Mark A. Schroeder

Publikováno v: Cancer Research. 74:2617-2617

GNE-317 is a dual PI3K/mTOR inhibitor with excellent blood-brain barrier penetration. In this study, the efficacy of GNE-317 was evaluated in the Mayo panel of primary glioblastoma multiforme (GBM) xenografts. Based on the concept of oncogene addicti

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b975401bf678f78882b8d9557881767f
https://doi.org/10.1158/1538-7445.am2014-2617

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání